Prevalencia del uso cotidiano de cannabis en la Unión Europea y Noruega

Aunque la prevalencia del consumo de cannabis el último año entre la población general se ha mantenido estable o a la baja en muchos países europeos, las demandas de tratamiento en el que el cannabis es la droga principal siguen aumentando. Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.

Cannabis use is relatively common in the European Union (EU) and Norway, with around 23 million people (6.8 % of all 15- to 64-year-olds) having used the drug in the past year and about 12 million (3.6 % of all 15- to 64-year-olds) in the last month. Although the prevalence of last-year cannabis use among the general population is generally stable or decreasing in many countries, demands for treatment in which cannabis is the primary drug continue to rise, indicating a possible increase in related problems. The substance is currently the most frequently mentioned drug by those demanding drug treatment for the first time in the EU and Norway. This suggests that, even though most cannabis use at the population level is likely to be transitory and at low levels, a significant minority of users use the substance intensively and/or for long periods of time. These patterns of use are reported to be associated with harms to the user and possibly with a need for treatment. Although this problem has been increasingly recognised, knowledge of the prevalence of the more intensive forms of cannabis use has been limited at the EU level.

This report brings together, for the first time in Europe, an integrated overview of the prevalence of intensive cannabis use, defined as daily or almost daily cannabis use (use on 20 or more days in the month preceding survey). Self-reported data regarding frequency of cannabis use from large, probabilistic, nationally representative samples of general population surveys from 20 countries, representing more than 83 % of the population of EU and Norway, were collected through two rounds of ad hoc data collection in 2004 and 2007 and through a routine, standard data collection instrument since 2010.

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.